Orientation Marketing appoints Sarah Darcy as sales operations executive
May 27, 2025Marketing Services, Sales and Marketing Corporate, pharmaceutical marketing agency, sales operations executive
Orientation Marketing has announced the appointment of Sarah Darcy as sales operations executive. She joins the business-to-business (B2B) life sciences and …
The Royal Marsden launches AI radiology platform to revolutionise cancer care
May 27, 2025Analytical & Laboratory Services, Market & Product Development, Medical Education, Research and Development AI, CARPL.ai., Institute of Cancer Research, NTT DATA, National Institute for Health and Care Research, Oncology, The Royal Marsden, oncology, radiology
The Royal Marsden, a world-leading cancer research centre, has launched a large-scale, AI-powered radiology platform designed to accelerate cancer detection …
MC2 Therapeutics appoints Trine Ahlgreen as new CEO
May 27, 2025Research and Development, Sales and Marketing CEO, Corporate, MC2 Therapeutics, Skin, inflammatory skin conditions
MC2 Therapeutics, a Danish pharma company focused on topical therapies for inflammatory skin conditions, has appointed Trine Ahlgreen as CEO. …
Moderna doses first US patient in phase 1 trial of mRNA-4106 for solid tumours
May 23, 2025Research and Development Moderna, Oncology, START Center for Cancer Research, US
The START Center for Cancer Research has dosed the first US participant in Moderna’s phase 1 clinical trial evaluating mRNA-4106, …
NICE recommends treatment for chronic kidney disease, IgA nephropathy
May 23, 2025Market & Product Development, Medical Communications, Research and Development IgA nephropathy, National Institute for Health and Care Excellence, Nephrology, kidney disease
The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending CSL Vifor’s FILSPARI (sparsentan) for …
CHMP issues positive opinion for Blenrep combinations in relapsed/refractory multiple myeloma
May 23, 2025Market & Product Development, Medical Communications, Research and Development Blenrep, Committee for Medicinal Products for Human USE, European Medicines Agency, Oncology, multiple myeloma
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion …
Sanofi to acquire Vigil Neuroscience, adding Alzheimer’s disease candidate to early-stage pipeline
May 23, 2025Mergers and Acquisitions, Research and Development Alzheimer's disease, Neurology, Sanofi, Vigil Neuroscience, neurodegenerative diseases
Sanofi has announced an agreement to acquire Vigil Neuroscience, a biotech company focused on therapies for neurodegenerative diseases. The deal …
PL BioScience and DewCell sign LOI to Jointly Develop Artificial Human Platelets for Scalable, Animal-Free Cell Culture Media
May 23, 2025Research and Development Animal-Free, Artificial Human Platelets, Corporate, DewCell, Haematology, Human Platelet Lysate, Letter of Intent, Oncology, PL Bioscience
PL BioScience and DewCell Biotherapeutics have signed a Letter of Intent (LOI) for the development and supply of artificial human …
Another Day Pharma announces successful Phase II trial results for BZ371A in post-prostatectomy erectile dysfunction
May 22, 2025Research and Development Another Day Pharma, Genito-Urinary system, clinical trial, erectile dysfunction, prostate cancer, prostatectomy
First-in-class therapeutic peptide BZ371A confirmed as effective and well-tolerated 20 May 2025. Another Day Pharma Ltd, a company developing innovative …
Tiakis Biotech appoints Christoph Schmidt to supervisory board
May 22, 2025Research and Development Cardiology, Tiakis Biotech, cardiovascular diseases, pulmonary arterial hypertension
Tiakis Biotech has announced the appointment of Christoph Schmidt to its supervisory board. Based in Kiel, Germany, the clinical-stage biotech …
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
May 22, 2025Market Access, Research and Development Haematology, Hympavzi, NHS, NICE, Pfizer, haemophilia B, marstacimab
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care Excellence (NICE) has published final …
Five Facts about mental health
May 21, 2025Medical Communications, Medical Education, Research and Development European Commission, Pharmacy, Psychiatry, mental health, mental health condition
32% of people suffer from at least one mental health issue, with daily struggles like financial and job insecurity being …
Novartis releases new data across oncology and haematology pipelines
May 21, 2025Research and Development ASCO, EHA, Haematology, Novartis, Oncology, oncology
Novartis has announced it will present new data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking …
Slingshot Therapeutics appoints Ed Savory as head of chemistry
May 21, 2025Research and Development Corporate, Pharmacy, Slingshot Therapeutics, appointment
Slingshot Therapeutics has announced the appointment of Ed Savory as head of chemistry. He will oversee the company’s chemistry strategy …
BioPhorum appoints Uwe Buecheler as non-executive director
May 21, 2025Medical Communications, Research and Development BioPhorum, Corporate, appointment, biopharma, medical communication
BioPhorum has announced the appointment of Uwe Buecheler as a non-executive director to its board. The company brings together leaders …
Multiple myeloma treatment approved in Japan
May 21, 2025Market Access, Research and Development, Sales and Marketing GSK, Japan, Oncology, Orphan Drug Designation (ODD), multiple myeloma
GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and Welfare for the treatment of …
FDA approves Incyte’s new anal cancer treatment
May 20, 2025Research and Development FDA, Incyte Corporation, Oncology, Orphan Drug Designation (ODD), Zynyz, fast track designation, priority review
The US Food and Drug Administration (FDA) has approved Incyte Corporation’s immunotherapy retifanlimab-dlwr (Zynyz) in combination with carboplatin and paclitaxel to treat …
Landmark BioVentures launches spin-off biotech to tackle fibrotic, neoplastic and neovascularised conditions
May 20, 2025Research and Development Aix-Marseille University, Cardiology, Corporate, Landmark BioVentures, Massalia Therapeutics, Oncology, cardiovascular research, oncology
Landmark BioVentures and researchers at Aix-Marseille University in Marseille, France, have launched Massalia Therapeutics. Marking Landmark’s seventh company, the spin-off …
Duck Creek Technologies appoints Tyler Jones as chief marketing officer
May 20, 2025Business Services, Pharmaceutical Consultancy Services Corporate, Duck Creek Technologies, appointment, chief marketing officer, property and casualty (P&C) insurance
Duck Creek Technologies has appointed Tyler Jones as its new chief marketing officer (CMO). He will lead the company’s global …
FDA approves diagnostic tool for MET-targeted lung cancer therapy
May 19, 2025Research and Development FDA, Oncology, Roche, lung cancer, non-squamous non-small cell lung cancer
The US Food and Drug Administration (FDA) has approved Roche’s VENTANA MET (SP44) RxDx Assay as a diagnostic tool to …
Latest content
FibroFind appoints Lee Borthwick as CEO
